Research programme: dual 5-lipoxygenase inhibitor and histamine H1 receptor antagonists - UCB ResearchAlternative Names: UBC 34743; UCB 62045; UCB34743
Latest Information Update: 17 Jul 2007
At a glance
- Originator UCB Research
- Mechanism of Action 5-lipoxygenase inhibitors; Histamine H1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Allergic rhinitis; Asthma
Most Recent Events
- 17 Sep 2002 Preclinical trials in Allergic rhinitis in Belgium (unspecified route)
- 17 Sep 2002 Preclinical trials in Asthma in Belgium (unspecified route)